Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

First Launch Commercialization Strategy: Go It Alone or Partner?

Posted by Renuka Agarwal on Fri, Feb 01, 2019

Ben Hohn, Cody Powers and Judith Kulich co-wrote this article with Renuka Agarwal.

The 2019 JPMorgan Chase Healthcare Conference kicked off with a bang as Eli Lilly announced its acquisition of Loxo Oncology for $8 billion. Loxo, a young biotechnology company that partnered with Bayer to launch its first asset, Vitrakvi, in 2018, isn’t a unique story: In today’s environment, the number of first launches for U.S.-based companies—defined by ZS as the first marketed assets of companies that have FDA “novel” status—is rapidly increasing. There were only three first launches from U.S.-based companies in 2011 compared to an astounding 16 first launches in 2018, primarily in oncology, according to ZS research.

Read More

Topics: Pharma, Pharma Industry, Life Sciences, commercial landscape, commercialization, european market, US-first launch, pharma commercial model, pharma strategy, JPMorgan Healthcare Conference, JPM2019

Four Takeaways From the Year’s Biggest—and Rainiest—Healthcare Conference

Posted by Ann Klein on Thu, Jan 31, 2019

Every year in early January, Union Square in San Francisco transforms from a shopping mecca to a (usually rainy) gathering of leadership teams from payers, large providers, life sciences companies and tech companies across the globe. The visual is dramatic: You’ll never see as many dark suits in San Francisco than when you’re wandering around town during the JPMorgan Healthcare Conference.

Read More

Topics: Pharma, Pharma Industry, Life Sciences, Google, JPMorgan Chase, health technology, JPMorgan Healthcare Conference, JPM2019, san francisco, software, Uber Health, health innovation

What the Changes in DTC Spending Mean for Pharma Companies

Posted by Sharon Suchotliff on Mon, Nov 12, 2018

Hensley Evans co-wrote this blog post with Sharon Suchotliff. 

In our previous blog post, we shared three key trends that are driving direct-to-consumer marketing into a state of flux. These forces—the exit of big DTC spenders due to loss of exclusivity, specialty brands driving investment in TV only, and shifts in consumer behavior and marketing mix—are behind the 4.7% decline in spending that we saw between 2016 and 2017.

Read More

Topics: Pharma Industry, digital marketing, DTC, consumer behavior, customer engagement journeys, pharma brands, pharma marketers, direct-to-consumer marketing, marketing mix, TV advertising, DTC marketing

As the Goalposts Keep Moving, Pharma Can Help Providers Continue to Move the Ball Forward

Posted by Paul Darling on Mon, Nov 20, 2017

As stakeholders throughout the healthcare ecosystem continue to transition from a fee-for-service model toward value-based care—and as providers try to keep up while feeling increasingly burdened by paperwork and disconnected from patients—the Centers for Medicare & Medicaid Services (CMS) keeps moving the goalposts.

Read More

Topics: customer centricity, Pharma, Pharma Industry, healthcare ecosystem, value-based care, patient centricity, bundled payments, collaboration

Highlights From ZS’s 2017 European Summit: What Industry Leaders Really Think About Patient Centricity in Pharma

Posted by Giorgio Lentini on Tue, Oct 31, 2017

Robert Selman and Ausrine Vaisvilaite co-wrote this blog post with Giorgio Lentini. 

Are we already patient-centric simply by talking about patients? Do patients define themselves by their medical conditions or by their roles in life as parents, family members or colleagues?

These were just some of the many questions discussed amongst participants at ZS’s European Summit, which took place in Basel, Switzerland, on Oct. 12.

Read More

Topics: Pharma, Pharma Industry, healthcare, Europe, EU, patient centricity, RWE, real-world evidence, patient centricity in R&D, ZS European Summit

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.